Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04895722 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008)
A Phase 2 study of Colorectal Cancer, sponsored by Merck Sharp & Dohme.
- Active
- Registry status
- Phase 2
- Development phase
- 302
- Enrollment target
- 20
- Study locations
NCT04895722 is a Phase 2 study of Colorectal Cancer that is active but no longer recruiting, run by Merck Sharp & Dohme. The registered enrollment target is 302 participants, below the 1,510-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (80% lower). The trial reports 20 study locations across 16 states.
The verdict
NCT04895722, a Phase 2 study of Colorectal Cancer, is active but no longer recruiting, sponsored by Merck Sharp & Dohme.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 302 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the efficacy and safety of co-formulated pembrolizumab/quavonlimab versus other treatments in participants with MSI-H or dMMR Metastatic Stage IV Colorectal Cancer.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- BIOLOGICAL MK-4830
- BIOLOGICAL Pembrolizumab/Quavonlimab
- BIOLOGICAL Pembrolizumab/Favezelimab
- BIOLOGICAL Pembrolizumab/Vibostolimab
Study Locations (20)
New York
- Icahn School of Medicine at Mount Sinai ( Site 1528) - New York
- Hematology Oncology Associates of Rockland ( Site 1525) - Nyack
Tennessee
- The West Clinic, PLLC dba West Cancer Center ( Site 1576) - Germantown
- Vanderbilt University Medical Center-Vanderbilt-Ingram Cancer Center ( Site 1509) - Nashville
Texas
- UT Southwestern Medical Center ( Site 1551) - Dallas
- Baylor Scott & White Medical Center - Temple-Division of Hematology/Oncology ( Site 1549) - Temple
Bruxelles-Capitale, Region de
- UZ Brussel ( Site 0105) - Brussels
- Cliniques universitaires Saint-Luc-Medical Oncology ( Site 0104) - Brussels
Florida
- Mid Florida Cancer Center ( Site 1519) - Orange City
Georgia
- University Cancer & Blood Center, LLC ( Site 1521) - Athens
Illinois
- University of Chicago Medical Center-Medicine - Section of Hematology/Oncology - Gastrointestinal P - Chicago
Pennsylvania
- UPMC Hillman Cancer Center ( Site 1516) - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 302 participants |
| Start Date | 2021-06-25 |
| Est. Completion | 2026-08-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04895722
The ClinicalTrials.gov registry entry for NCT04895722 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 302 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,510-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (80% lower). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Colorectal Cancer appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT04895722 reports 20 study locations spanning 16 distinct geographic areas - top geographies include New York, Tennessee, Texas.
Frequently Asked Questions
What is clinical trial NCT04895722 about?
NCT04895722 is a clinical study titled "Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008)". The purpose of this study is to assess the efficacy and safety of co-formulated pembrolizumab/quavonlimab versus other treatments in participants with MSI-H or dMMR Metastatic Stage IV Colorectal Cancer.
What is the current status of trial NCT04895722?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 302 participants. The study started on 2021-06-25. Estimated completion is 2026-08-13.
What conditions does trial NCT04895722 study?
This clinical trial studies the following conditions: Colorectal Cancer.
What interventions are being tested in trial NCT04895722?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), MK-4830 (BIOLOGICAL), Pembrolizumab/Quavonlimab (BIOLOGICAL), Pembrolizumab/Favezelimab (BIOLOGICAL), Pembrolizumab/Vibostolimab (BIOLOGICAL).
Who is sponsoring clinical trial NCT04895722?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04895722 being conducted?
This trial has 20 study locations across Florida, Georgia, Illinois, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
RECRUITING · Phase 2
-
A Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) Guided by Magnetic Resonance Imaging (MRI) in People With Liver Metastasis From Colorectal Cancer
RECRUITING · Phase 2
-
TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
RECRUITING · Phase 2
-
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
RECRUITING · Phase 2
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.